204 related articles for article (PubMed ID: 16627760)
21. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group.
Cavé H; van der Werff ten Bosch J; Suciu S; Guidal C; Waterkeyn C; Otten J; Bakkus M; Thielemans K; Grandchamp B; Vilmer E
N Engl J Med; 1998 Aug; 339(9):591-8. PubMed ID: 9718378
[TBL] [Abstract][Full Text] [Related]
22. Sequential monitoring of minimal residual disease in acute lymphoblastic leukemia: 7-year experience in a pediatric hematology/oncology unit.
Katsibardi K; Moschovi MA; Braoudaki M; Papadhimitriou SI; Papathanasiou C; Tzortzatou-Stathopoulou F
Leuk Lymphoma; 2010 May; 51(5):846-52. PubMed ID: 20350276
[TBL] [Abstract][Full Text] [Related]
23. Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL).
Kwok CS; Kham SK; Ariffin H; Lin HP; Quah TC; Yeoh AE
Pediatr Blood Cancer; 2006 Sep; 47(3):299-304. PubMed ID: 16302217
[TBL] [Abstract][Full Text] [Related]
24. Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia.
Cario G; Stanulla M; Fine BM; Teuffel O; Neuhoff NV; Schrauder A; Flohr T; Schäfer BW; Bartram CR; Welte K; Schlegelberger B; Schrappe M
Blood; 2005 Jan; 105(2):821-6. PubMed ID: 15388585
[TBL] [Abstract][Full Text] [Related]
25. [Clinical significance of glucocorticoid induction test in Chinese childhood acute lymphoblastic leukemia].
Fan JJ; Chai YH; Hu SY; He HL; Zhao WL; Wang Y; Li J; Lu J; Xiao PF; Sun YN; Wang W; Cao L
Zhonghua Er Ke Za Zhi; 2013 Jul; 51(7):523-6. PubMed ID: 24267134
[TBL] [Abstract][Full Text] [Related]
26. Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia.
Stow P; Key L; Chen X; Pan Q; Neale GA; Coustan-Smith E; Mullighan CG; Zhou Y; Pui CH; Campana D
Blood; 2010 Jun; 115(23):4657-63. PubMed ID: 20304809
[TBL] [Abstract][Full Text] [Related]
27. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia.
Coustan-Smith E; Sancho J; Hancock ML; Boyett JM; Behm FG; Raimondi SC; Sandlund JT; Rivera GK; Rubnitz JE; Ribeiro RC; Pui CH; Campana D
Blood; 2000 Oct; 96(8):2691-6. PubMed ID: 11023499
[TBL] [Abstract][Full Text] [Related]
28. [The clinical significance of detecting minimal residual disease in acute childhood B-cell lymphoblastic leukemia with flow cytometry].
Zhang LP; Cheng YF; Liu GL; Lu AD; Liu YR; Wang H
Zhonghua Er Ke Za Zhi; 2005 Jul; 43(7):481-5. PubMed ID: 16083543
[TBL] [Abstract][Full Text] [Related]
29. Minimal residual disease after intensive induction therapy in childhood acute lymphoblastic leukemia predicts outcome.
Gruhn B; Hongeng S; Yi H; Hancock ML; Rubnitz JE; Neale GA; Kitchingman GR
Leukemia; 1998 May; 12(5):675-81. PubMed ID: 9593264
[TBL] [Abstract][Full Text] [Related]
30. A simplified minimal residual disease polymerase chain reaction method at early treatment points can stratify children with acute lymphoblastic leukemia into good and poor outcome groups.
Scrideli CA; Assumpção JG; Ganazza MA; Araújo M; Toledo SR; Lee ML; Delbuono E; Petrilli AS; Queiróz RP; Biondi A; Viana MB; Yunes JA; Brandalise SR; Tone LG
Haematologica; 2009 Jun; 94(6):781-9. PubMed ID: 19483156
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia.
Ciudad J; San Miguel JF; López-Berges MC; Vidriales B; Valverde B; Ocqueteau M; Mateos G; Caballero MD; Hernández J; Moro MJ; Mateos MV; Orfao A
J Clin Oncol; 1998 Dec; 16(12):3774-81. PubMed ID: 9850021
[TBL] [Abstract][Full Text] [Related]
32. Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia.
Chen JS; Coustan-Smith E; Suzuki T; Neale GA; Mihara K; Pui CH; Campana D
Blood; 2001 Apr; 97(7):2115-20. PubMed ID: 11264179
[TBL] [Abstract][Full Text] [Related]
33. [Effects of minimal residual disease level on day 33 of remission induction and IKZF1 genotype on the survival of children with B-lineage acute lymphoblastic leukemia].
Kuang WY; Zheng MC; Li WL; Yang HX; Zhang BS; Wu P
Zhongguo Dang Dai Er Ke Za Zhi; 2018 Jul; 20(7):538-542. PubMed ID: 30022754
[TBL] [Abstract][Full Text] [Related]
34. Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia.
Paganin M; Zecca M; Fabbri G; Polato K; Biondi A; Rizzari C; Locatelli F; Basso G
Leukemia; 2008 Dec; 22(12):2193-200. PubMed ID: 18754029
[TBL] [Abstract][Full Text] [Related]
35. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia.
Sramkova L; Muzikova K; Fronkova E; Krejci O; Sedlacek P; Formankova R; Mejstrikova E; Stary J; Trka J
Pediatr Blood Cancer; 2007 Jan; 48(1):93-100. PubMed ID: 16521130
[TBL] [Abstract][Full Text] [Related]
36. Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia.
Steenbergen EJ; Verhagen OJ; van Leeuwen EF; van den Berg H; Behrendt H; Slater RM; von dem Borne AE; van der Schoot CE
Leukemia; 1995 Oct; 9(10):1726-34. PubMed ID: 7564517
[TBL] [Abstract][Full Text] [Related]
37. [Prognostic value of both detection of lymphoblasts in the period of early treatment and minimal residual disease in childhood acute lymphoblastic leukemia].
Tie LJ; Gu LJ; Song DL; Jiang LM; Xue HL; Tang JY; Dong L; Pan C; Chen J; Ye H; Wang YP; Chen J
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):6-9. PubMed ID: 15946500
[TBL] [Abstract][Full Text] [Related]
38. Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.
Jeha S; Coustan-Smith E; Pei D; Sandlund JT; Rubnitz JE; Howard SC; Inaba H; Bhojwani D; Metzger ML; Cheng C; Choi JK; Jacobsen J; Shurtleff SA; Raimondi S; Ribeiro RC; Pui CH; Campana D
Cancer; 2014 May; 120(10):1514-9. PubMed ID: 24501014
[TBL] [Abstract][Full Text] [Related]
39. Absolute lymphocyte counts refine minimal residual disease-based risk stratification in childhood acute lymphoblastic leukemia.
Rabin KR; Gramatges MM; Borowitz MJ; Palla SL; Shi X; Margolin JF; Zweidler-McKay PA
Pediatr Blood Cancer; 2012 Sep; 59(3):468-74. PubMed ID: 22102553
[TBL] [Abstract][Full Text] [Related]
40. E2F3a gene expression has prognostic significance in childhood acute lymphoblastic leukemia.
Wang KL; Mei YY; Cui L; Zhao XX; Li WJ; Gao C; Liu SG; Jiao Y; Liu FF; Wu MY; Ding W; Li ZG
Eur J Haematol; 2014 Oct; 93(4):281-9. PubMed ID: 24758291
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]